Welcome to Rutgers NanoBioTechnology Laboratory
The high cost of diagnostic exams in the clinical setting has resulted in a healthcare crisis both nationally and globally. The lack of sensitivity in current state-of-the-art biosensing platforms used in the clinical setting has resulted in slow and expensive diagnostic exams. This makes it economically unfeasible to regularly screen patients for a wide panel of biomarkers, making impossible the diagnosis of diseases at early stages while still curable. By making use of the advantages offered by micro and nanotechnologies, we aim to develop sensing platforms which will decrease cost, increase assay speed, and improve limit of detection in biomolecular assays. Increasing sensitivity can enable earlier detection, and also can allow for identification of low-abundance markers that are not detectable with current techniques. Also of importance is to resolve various bottlenecks that currently impede the ability of a protein assay to be performed in high throughput, such as antibody cross reactivity. Currently in antibody arrays, antibody cross reactivity limits the ability to analyze more than 20 markers in parallel, which has paralyzed advance in protein biomarker discovery for cancer biology and other fields. A separate problem is that, despite their clinical relevance, detection of small molecule metabolites is difficult using gold standard fluorescent techniques due to the need for labeling them which will result in chemically modifying their structure.